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SCIENCE ADVANCES | RESEARCH ARTICLE
HEALTH AND MEDICINE

Biological resurfacing in a canine model of
hip osteoarthritis
Bradley T. Estes1*†, Masataka Enomoto2†, Franklin T. Moutos1, Megan A. Carson3, Jeffrey M. Toth4,
Peter Eggert4, Jonathan Stallrich5, Vincent P. Willard1, Deborah J. Veis6,7,8, Dianne Little9,
Farshid Guilak1,7,10,11*‡, B. Duncan X. Lascelles2,12,13,14*‡
Articular cartilage has unique load-bearing properties but has minimal capacity for intrinsic repair. Here, we used
three-dimensional weaving, additive manufacturing, and autologous mesenchymal stem cells to create a tissue-
engineered, bicomponent implant to restore hip function in a canine hip osteoarthritis model. This resorbable
implant was specifically designed to function mechanically from the time of repair and to biologically integrate
with native tissues for long-term restoration. A massive osteochondral lesion was created in the hip of skeletally
mature hounds and repaired with the implant or left empty (control). Longitudinal outcome measures over 6 months
demonstrated that the implant dogs returned to normal preoperative values of pain and function. Anatomical
structure and functional biomechanical properties were also restored in the implanted dogs. Control animals never
returned to normal and exhibited structurally deficient repair. This study provides clinically relevant evidence
that the bicomponent implant may be a potential therapy for moderate hip osteoarthritis.
INTRODUCTION

Osteoarthritis (OA) is a degenerative disease affecting all components
of the joint, characterized by progressive damage to the articular
cartilage and underlying bone. While the primary treatment for
end-stage OA is a total joint replacement, long-term follow-up
studies show that up to one-third of patients under the age of 40 at
the time of total hip arthroplasty have loosening or excessive wear
problems later in life (1). Thus, any procedures that serve to postpone
joint replacement and preserve the joint would have a substantial
clinical benefit. However, alternative biologic techniques, such as
osteochondral transfer or microfracture procedures, are ineffective
for larger lesions (2, 3). Second-generation autologous chondrocyte
implantation or matrix-assisted chondrocyte implantation procedures
are not approved for use outside the knee joint and report an almost
30% failure rate within 9 years in young patients (4–6). There is a
need for improved techniques, implants, and procedures to effectively
treat the disease or, at a minimum, delay the progression of OA
to the point at which the patients are better candidates for a hip
arthroplasty procedure.
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In our previous work, we have developed a unique cartilage repair
implant using a textile manufacturing process of three-dimensional
(3D) orthogonal weaving to form a construct that is biomechanically
and biologically designed for cartilage repair (7–11). One of the
principal advantages of this biomimetic structure is that it enables
the implantation of a device that has been optimized to support the
loads in the joint while providing a conduit for endogenous cell
infiltration, tissue synthesis, and integration with native tissues for
long-term functional support (12). This approach is in direct contrast to the use of many biomaterials used to date for cartilage tissue
engineering, which do not have the mechanical properties and
load-bearing characteristics of native cartilage until significant
matrix deposition has occurred over time. The basis of this technology
is a 3D “microweave” of fibers in three orthogonal directions. In
comparison to standard weaving methods, this process eliminates
fiber crimp and forms a true 3D structure that can be tuned in tension,
compression, and shear to match native cartilage properties. Most
current 3D textile composite materials are constructed by laminating
multiple 2D structures together; here, the use of a true 3D woven
structure eliminates the weak interfaces between multiple layers in
the structure, where delamination can occur. Furthermore, the controlled regularity and interconnectivity of the woven pore structure
allow cells to be easily loaded and uniformly distributed within the
scaffold upon which they are able to synthesize a robust extracellular
matrix (Fig. 1) (7, 9, 10, 13). The regular pore geometry also facilitates nutrient diffusion along regular and continuous paths throughout the scaffold (7). These properties have been optimized to mimic
the functional properties of articular cartilage and have demonstrated their ability to sustain functional properties over extended
in vitro culture (7, 9, 10, 13). To enhance stable integration of the
3D woven textile into the bone bed, an additively manufactured porous
base has also been integrated into the implant (Fig. 1, F and G). This
type of structure has been shown in previous work to promote
osteogenesis of transplanted stem cells by stimulating signaling
pathways that enhance osteogenesis (14).
The objective of this work was therefore to test the ability of this
bicomponent tissue-engineered construct to replace most of the
1 of 13
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Fig. 1. Implant configuration and surgical procedure. (A) The cartilage component is constructed of a 3D woven textile, and (B) additive manufacturing is used to
make a printed base, which, when fused together, form the (C) final bicomponent
implant (D) 10 mm in diameter by ~2 mm deep. (E) 3D schematic of the woven textile
demonstrating orthogonality of the structure. (F and G) Scanning electron microscopy
images demonstrate bonding and encapsulation (black arrow) of woven yarns
(white arrows) in the first layer of the printed PCL component (black asterisks).
Scale bars, 100 m. (H) MSC seeding (green fluorescence) is followed by (I) expansion, differentiation, and tissue development ex vivo. (J) Control defect site and
(K) implant disposition are shown at the time of surgery. (L) A capsulorrhaphy procedure, standard in the canine model, was used to stabilize the joint. Photo credit:
Franklin Moutos, Cytex Therapeutics Inc.

load-bearing cartilage surface of the femoral head in a large animal
model, using autologous bone marrow–derived mesenchymal stem
cells (MSCs) on an anatomically shaped 3D woven scaffold (7, 10, 11).
Our hypothesis was that a scaffold engineered to mimic many of the
mechanical properties of the native tissue with sufficient porosity
for cell ingrowth and tissue differentiation (7–9, 11) could restore
the articular surface structure and, thereby, also restore normal
function to the joint. To test this hypothesis, we used a canine model
of hip OA, because of its similarities in the human hip, and collected
quantitative functional outcome data longitudinally throughout the
6-month duration of the study (15–17). The bicomponent nature
of the 3D woven textile and additively manufactured base enable
a novel treatment paradigm for osteochondral repair for large lesions that cannot be repaired with current bone marrow stimulation techniques.
RESULTS

Outcome measures in this study were primarily focused on behavioral measures of joint pain and function (i.e., gait analysis), with
concomitant analysis of the structural integrity and mechanical
properties of the regenerated tissues at the 6-month termination of
the study.
Estes et al., Sci. Adv. 2021; 7 : eabi5918
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Gait analysis, limb girth, pain, and actimetry
The implant group trended toward baseline in all gait analysis measures and was also found to return to baseline in three of the five
measures (Fig. 2). For peak vertical force (PVF), which is one of the
principal components for quantifying lameness, the implant group
indicated better limb use, quantified as 6.82 ± 2.23% body weight
(BW) larger than the control group’s average across all time points
(Fig. 2A). The animals receiving the implant returned to baseline
PVF by month 3. For vertical impulse (VI), another principal measure for quantifying lameness, the implant group returned to normal
by the sixth month, and over the 6-month period, the implant average was 0.67 ± 0.19% BW·s larger than the control group animals,
also indicating better limb use (Fig. 2B). Both implant and control
groups did not return to baseline for peak propulsion force (PPF)
and propulsion impulse (PI), but it was noted that the implant group
was trending toward baseline faster than the control group for both
measures (Fig. 2, C and D). Although body weight distribution returned to baseline for both implant and control groups, that return
happened 1 month earlier for the implant group than it did for the
control group (Fig. 2E). Along with the gait analysis measures, the
discrepancy in limb girth between operated and unoperated contralateral limb trended toward normal at a faster rate in the implant
group than the control group, but neither group returned to baseline
over the duration of the study (Fig. 2F). This finding was confirmed
by computed tomography (CT) analysis at the end of the study when
comparing the cross-sectional area of the thigh of the experimental
limb to the contralateral, unoperated limb. The control animals had
a −15.3 ± 8.1 cm2 difference (operated minus unoperated) in area,
and the implant animals had a −5.3 ± 4.3 cm2 difference in area. For
pain, as measured by the Canine Research Orthopedic Pain Inventory
(CROPI-h; see also fig. S1), the implant group’s score was 6.82 ±
2.23 smaller (less pain and impairment) than the control group’s
average across all time periods, and the dogs receiving the implant
returned to normal preoperative levels of pain and function by the
second month of the study (Fig. 2G and fig. S1). Body weight for all
animals within each group was consistent throughout the study
period (Fig. 2H).
Overall, the (negative) effect on activity was greater in the control group than implant group (Fig. 3), with the implant group regaining baseline activity by the end of the first postoperative month
when examining peak hours of activity (Table 1). Significant treatment effects were observed at each monthly interval (P = 0.0031).
Significant interactive effects were also noted, particularly month*hour
(P < 0.05) and treatment*hour (P < 0.0001) as observed by the different trends in the two peaks of activity measured when the animals
were interacting with the care technicians. Averaged across the
6-month period, significant differences were noted between the hours
of 7:00 a.m. and 4:00 p.m.
Variables of time (i.e., month of analysis) and treatment (control
versus implant) were significant for measured values of gait analysis,
limb girth, and CROPI-h (Table 1); however, no time/treatment interactive effects were observed in the study. A treatment effect was
insignificant in only two of the nine measures: static body weight
distribution and OA radiographic score.
Radiographic scores of OA and synovium histology;
organ pathology
Ventral-dorsal radiography demonstrated no noticeable issues in the
implant group, although bone loss and exostosis in ring form were
2 of 13
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Fig. 2. Gait analysis. Measured kinetic GRF indices including (A) PVF, (B) VI, (C) PPF, and (D) PI (all based on % BW) rapidly returned to baseline in the implant group;
conversely, the empty defect group kinetic indices never returned to normal. (E) Body weight distribution of the operated limb in standing (measured by a pressure-sensitive
walkway) showed a return to baseline in both groups. Data are presented as change from baseline, normalized by BW. (F) Change in limb circumference as measured by
the difference between operated limb and contralateral unoperated limb indicates recovery of muscle volume in the implant group and persistent atrophy in the empty
defect group, *P < 0.05. (G) Pain scores (CROPI-h) were consistently lower in the implant group compared to the control group; however, no time/treatment interaction
was observed (P = 0.075). (H) Weights of animals throughout the study. Means ± SD with a two-factor (treatment and time) ANCOVA model were used with responses dijk
and covariate xij: Overall time and treatment effect P values are noted on figures, no time*treatment interactive effects were observed in any of the measures. # indicates
no difference from baseline in the implant group; $ indicates no difference from baseline in the control group, P < 0.05.

evident in the control group (Fig. 4A). OA radiographic scoring
indicated normal joint findings for the implant group in months 1
and 2, while significant differences were noted between preoperative
values and postoperative radiographic markers for all time points
following surgery in the control animals (Fig. 4, B and C). Mild
synovitis was observed on all operated hip joints (Fig. 4, D and E).
While no significant differences were noted between control and
implant synovium, trends of higher chronic inflammation and
synovial hyperplasia, along with more giant cells, were observed in
the untreated joints than in the implant joints (Fig. 4F). Heart, kidney,
spleen, lung, liver, and skeletal muscle all showed no aberrant
pathology, including inflammation. Regional lymph nodes showed
mild reactive changes, including scattered giant cells that were likely
related to the surgical procedure, as they were similar in control and
implant groups.
Cartilage and subchondral bone: Gross and histological
findings, immunohistological findings, and day 0
biochemical findings
No depressions were observed in the implant-treated femoral heads
(Fig. 5, A to C), and the surface of the implant appeared to be
smooth with no surface irregularities. In contrast, control defects
showed depressions into the osteochondral bone (Fig. 5, D to F)
with only fibrous connective tissues in the osteochondral defects
Estes et al., Sci. Adv. 2021; 7 : eabi5918
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(Fig. 5G). Cartilaginous tissue ingrowth and overgrowth occurred both
in and on the woven phase of the bicomponent device (Fig. 5, H and I),
and a consistent finding was that these tissues appeared to be bonded
to adjacent cartilage at the periphery of the device with no fissures
at either end of the device (Fig. 5, J and K). In addition, a limited
amount of bone integrated with the printed portion of the implant
was observed with no fissures between the implant and the surrounding bone (Fig. 5, I and M). Tissue filling the pores between the
poly(-caprolactone) (PCL) printed struts consisted primarily of
fibrous tissue (Fig. 5L). Microradiographs showed no reduction in
bone mineral density adjacent to the implant and minimal ingrowth
into the textile component of the implant (Fig. 5M). Typical cross
sections of the implant demonstrated fibrous overgrowth, complete
tissue infilling of the pores in both components of the implant
(i.e., both textile and printed portions) with the implant intact at this
6-month terminal time point (Fig. 5N). Rounded chondrocyte-like
cell morphology within the pore structure of the textile was also
observed (Fig. 5O). There was no inflammation observed in peri-
implant tissues. In addition, there were no changes in the histological
sections of the acetabula in either the control or implant hips.
Immunohistochemical labeling for collagen types I and II revealed
fibrous structure in the textile component alone containing both
collagens at the time of implantation (Fig. 6). The empty defect control group was completely filled with type I collagen only, while the
3 of 13
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were observed at each monthly interval (P = 0.0031). Significant interactive effects
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(*P < 0.05 and +P < 0.0001). The implant group returned to baseline at hours 7 and
14 in month 1, while the control group never returned to baseline. # indicates no
difference from baseline in the implant group at hours 7 and 14.

implant contained a mixture of both type I and II collagen at the
6-month time point. These collagens were found colocalized in
both the textile and printed components of the implants (Fig. 6).
Dimethylmethylene blue normalized to double-stranded DNA (dsDNA)
and hydroxyproline (OHP) normalized to dsDNA revealed sulfated
glycosaminoglycan (sGAG)/DNA at 12.39 g/g and total collagen/
DNA of 102.1 g/g for day 0 constructs (18).
Modified O’Driscoll scores showed that the control group had the
greatest reduction in histology scores, whereas the implant group had
significantly higher scores, indicating histology closer to baseline
than untreated defects (Fig. 7). Eleven of the 12 unoperated normal
(i.e., contralateral) femoral heads had a histology score of 20/20 and
was 18/20 in the other. The range for the control defects was 6 to 9
and 13 to 14 for the implants. There was a significant difference
between the two groups (P = 0.0001) for the operated to unoperated
difference in histology score. The average difference in the control
group was −13.0 ± 0.63 (SEM), and in the implant group, it was −6.8 ±
0.17. In comparing the implant to the unoperated cartilage control,
the implant was not significantly different in five of the eight components of this scoring rubric, which included surface irregularity,
Estes et al., Sci. Adv. 2021; 7 : eabi5918

15 September 2021

cartilage level, adjacent cartilage bonding, presence of inflammatory
cells, and chondrocyte clustering. The measures that were significantly
different were subchondral bone regeneration, freedom from adjacent
tissue degeneration, and hyalinity (Fig. 7).
Mechanical properties
At the time of implantation, the implants had a mean compressive
instantaneous modulus of 5.93 MPa with a mean compressive equilibrium modulus of 4.61 MPa. After 6 months in vivo with significant
tissue both in and on top of the surface of the implants, both the
instantaneous and equilibrium moduli of the implant were significantly decreased from day 0 values to 0.99 and 0.46 MPa, respectively.
Significant differences were observed in the mechanical properties
of the implant repair tissue as compared to control tissue, with a
greater than 10-fold higher modulus in the implant group (equilibrium modulus: 0.460 MPa versus 0.039 MPa for the implant and
control groups, respectively; instantaneous modulus: 0.99 MPa
versus 0.293 MPa for the implant and control groups, respectively)
(P < 0.05). The instantaneous modulus of the contralateral control
(unoperated) was approximately 4-fold higher than the repair tissue
with the implant group but was 15-fold higher than the instantaneous
modulus measured in the empty defect repair tissues (P < 0.0001).
The equilibrium modulus of the contralateral control cartilage was
more than 2-fold greater than the repair tissue in the implant group
(P < 0.05) but was more than 30-fold higher relative to the empty
defect repair tissue (P < 0.0001) (Fig. 8).
DISCUSSION

The findings of this study show that an anatomically shaped tissue-
engineered implant consisting of an interconnected 3D woven and
3D printed composite can provide functional restoration of massive
osteochondral defects in the hip joint. Excellent integration of this
MSC-seeded construct was observed in all cases, and no failures were
observed. Pain and function outcomes in the animals receiving the
construct showed significant improvement by the first measured
time point (1 month) and demonstrated a return to normal preoperative values by the 6-month time period. The implants showed
mechanical properties approaching those of normal cartilage, as
compared to unfilled defects, which showed a compressive modulus
of less than 10% that of implant tissues.
The primary objective measures used in this study were derived
from biomechanical analysis to determine the functional response
of joint restoration following the creation of a massive (10 mm)
defect in the hip. This massive defect comprised approximately 60%
of the major load-bearing surface of the femoral head and is much
larger than what is typically observed in clinical practice. In context,
the created lesion was approximately twice the size of early clinical
lesions in this area that are associated with clinical signs of OA in
dogs. An empty defect alone served as a control for the implant group
since, clinically, the size of the lesion would not spontaneously heal
and would also progressively lead to joint degeneration. In addition,
the bone preparation used was effectively a bone marrow stimulation
technique that is analogous to techniques that are currently used
clinically, such as microfracture. Gait analysis has been validated as
an objective measure of changes in limb use as it relates to joint pain
in dogs and humans (19, 20). The decrease in kinetic ground reaction forces (GRFs) from baseline to 6 months following surgery
in the control group was similar to the difference between that in
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P = 0.0089
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P > 0.05
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Time*
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*Additional time/hour interaction for the actimetry data, P = 0.036.

OA
radiographic
score

Limb girth

P < 0.05

P < 0.05

Activity at 2:00
p.m.*

CROPI-h

P < 0.05

P = 0.0063

P < 0.05

Activity at 7:00
a.m.*

Static body
weight
distribution

Propulsion
impulse

P < 0.005

P < 0.005

Vertical
impulse

Peak
propulsion
force

P < 0.0005

Time (month)

Peak vertical
force

Measure

2.59 ± 0.96

−4.59 ± 0.37

36.82 ± 5.89

−220.52 ± 39.79

−196.54 ± 47.97

−11.50 ± 2.12

−0.36 ± 0.03

−3.80 ± 0.31

−2.52 ± 0.25

−14.15 ± 1.54

First month control
avg. − baseline avg.

1.41 ± 0.96

−3.00 ± 0.37

30.01 ± 5.89

−41.19 ± 40.99

−20.03 ± 49.34

−8.89 ± 2.12

−0.25 ± 0.03

−2.82 ± 0.31

−1.85 ± 0.25

−9.39 ± 1.54

First month
implant avg. −
baseline avg.

Table 1. Summary of statistical findings relative to baseline. “Control,” control group; “Implant,” implant group.

4.67 ± 0.77

−2.85 ± 0.34

10.24 ± 1.88

−249.49 ± 39.73

−118.69 ± 47.93

−2.50 ± 1.13

−0.23 ± 0.03

−1.84 ± 0.27

−1.02 ± 0.18

−3.86 ± 1.05

Sixth month
control avg. −
baseline avg.

3.49 ± 0.77

−1.25 ± 0.34

3.43 ± 1.88

−80.86 ± 40.93

47.13 ± 49.28

0.11 ± 1.13

−0.11 ± 0.03

−0.86 ± 0.27

−0.35 ± 0.18
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arrows indicating examples of giant cells. H&E histology stain: Scale bars, 0.1 mm. (F) Semiquantitative scoring of synovial tissues (maximum score of 3: normal, 0; mild, 1;
moderate, 2; and severe, 3) for chronic inflammation severity, synovial hyperplasia severity, and the presence of giant cells. Further details of the scoring matrix are provided in table S1.

clinically sound dogs and dogs with naturally occurring hip OA, as
well as that in humans between patients with OA and non-OA
patients (21). Furthermore, the return toward normal GRFs by 3 to
6 months following the surgery in the implant group was similar to
the changes following successful total hip replacement (THR) in dogs
(19, 22). Seibert and colleagues (22) reported PVF and VI of pet dogs
with diagnosed OA and undergoing THR. On average, the animals
with naturally occurring OA had PVF deficits of 7.5% BW relative
the contralateral limb, similar to the difference between the operated
and control limbs of the control group (empty defect) dogs (~5% BW).
THR in pet dogs resulted in a 3.65% BW improvement in limb use
(with up to 12 months of follow-up), and in our study, the difference in PVF between the control and seeded group was ~11% BW
at 6 months. Similarly, VI of the operated limb in pet dogs was increased approximately 1% after hip replacement, also in line with the
difference between control and seeded scaffold groups at 6 months
(1%) (22). Together, GRF data obtained in the current study suggest
equivalent or greater functional outcomes to that which is obtained
with total hip arthroplasty, which is validating for our approach. It
is well established that a THR alleviates pain and lameness in the
canine hip (23), and the fact that we obtained equivalent changes in
both PVF and VI strongly suggests palliation of pain and lameness,
which was also confirmed across our measures in the present study.
Although there were no significant differences between groups, an
analysis of body weight distribution to the operated limb at 6 months
following surgery in the implant group was closer to baseline than
the control (empty defect) group. The increase in the body weight
distribution of ~10% over the 6-month study in the implant group
over time is completely consistent with what was observed in a previous study for dogs with a unilateral THR in dogs (17) and in humans
that had undergone unilateral total hip arthroplasty (24). Overall, dynamic and static GRFs suggest that our biological resurfacing technique restores limb function following surgery.
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Additional measures of the efficacy of this procedure were made
using activity measurement with accelerometers, which provide a
validated surrogate measure of movement as a measure of pain and
function (25) and have successfully been used to detect changes in
activity related to analgesic therapies in clinical OA studies in dogs
(26). In the present study, we observed significant reductions in
activity in the control (empty defect) group, indicative of ongoing
pain and functional deficits that persisted throughout the 6-month
study period. However, in the implant group, no significant differences between baseline and overall postoperative activity levels were
observed, indicating an absence of pain. In terms of patterns of
activity, we observed a bimodal pattern, similar to that that has been
described in research in pet dogs (25, 26). The peaks of activity were
primarily affected in the present study in the control (empty defect)
dogs, and these peaks represent more intense activity. The provision
of effective analgesia (anti–nerve growth factor monoclonal antibody)
in pet dogs similarly affected these peaks of activity (26). These measurements are consistent with the patterns of reduced activity observed in humans with OA compared to healthy humans (27).
The change from baseline in limb girth, as calculated by the difference between operated and unoperated contralateral limb,
mirrored the change from baseline in limb use. In the implant group,
limb circumference increased as kinetic variables returned to preoperative values, whereas the control group’s limb circumference
never returned to the baseline, matching the reduced limb use. This
relationship between limb use and muscle mass is similar to what is
seen in humans (28). The limb girth measurements were supported
by the objective measurement of thigh muscle cross-sectional area
using CT, and there was a significant correlation between these two
measures (r = 0.58, P = 0.0063) at the 6-month time point.
A critical design parameter of the tissue-engineered implant was
the ability to reproduce the mechanical properties and anatomic
structure of the cartilage defect from the initial time of implantation.
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Fig. 5. Gross findings/histology. (A to C) The smooth implant contour typically matched native anatomy (dog 6) (black arrows). Round ligament is visible (black arrowheads).
(D to F) Empty defects (left to right: dogs 7, 2, and 7) (black arrows) showed significant fibrocartilage filling. (G) Mallory Aniline Blue (MAB) of empty defects (dog 13)
showed unhealed fibrous-filled depressions (white asterisk − dotted line = ~original articular surface). Inset (millimeter scale): Magnification of defect. (H) Undecalcified
implant section (dog 6) revealed host tissue integration and a smooth surface without irregularities (black triangle). Trichrome (millimeter scale) (I) with limited new bone
formation (white asterisk). (J) Undecalcified section (dog 11) (trichrome) demonstrates congruency with native surfaces (black arrowhead). Z-fiber (black arrow) presence
demonstrates implant integrity. (K) Representative Safranin O/Fast Green staining (dog 12) showed fibrous bonding to adjacent cartilage at defect margins (black arrows)
(79×). (L) H&E (dog 11) showing fibrous tissue (white asterisk) around PCL struts (79×). (M) Representative microradiograph (dog 11) revealed limited bone formation
within the base (white arrows). (N) Decalcified histology (dog 6) showed fibrous growth in/on the implant (MAB, 31×) (O) and few chondrocytes (dog 10) in the implant
woven component (black arrows) (Alcian blue–periodic acid–Schiff, 79×). See figs. S2 to S8 and table S2 for all animal images. Photo credit: Bradley Estes, Cytex Therapeutics Inc.

These properties were conferred by the 3D orthogonal weaving
method that was “tuned” to match the implant properties a priori
(9, 11). Tissue development in the implant served to significantly
decrease the modulus values relative to day 0, revealing the contribution of the newly synthesized and remodeled tissue on the mechanical behavior of the biosynthetic composite. Regardless of the
relative mechanical contribution of the PCL-based bicomponent
Estes et al., Sci. Adv. 2021; 7 : eabi5918
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implant and the newly synthesized tissues, our results confirm the
restoration of the native anatomical contours with a hybrid biologic/
synthetic implant that exhibited native cartilage compressive values.
During the culture of the constructs, we only observed filling of the
textile component with small amounts of de novo tissue (Fig. 6), but
no tissue was synthesized in the printed component. Accordingly,
all tissue that is observed in the printed base was synthesized in vivo
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over the 6-month period. The fact that the initial printed base was
devoid of cells and tissue at day 0 could account for why little bone
development had occurred in the printed component of the implant,
and perhaps, future studies using longer survival times may allow
for this bone tissue development. Immunohistochemical labeling
for type I and II collagen revealed only type I collagen in the empty
defects, whereas colocalization of collagen types I and II is present
in the implant group. These data suggest that the PCL implant is
inducing (or, at a minimum, is conducive to) a more cartilage-like
phenotype due to the production of type II collagen. The integration of this structure with native tissues allowed a seamless transition from native, preexisting tissue to de novo tissue, such that the
Day 0
Baseline

6 months
Unoperated
cartilage

Empty
defect

Implant

Fig. 6. Immunohistochemical labeling for collagen I and II at day 0 and after
6 months in vivo. Scale bars, (day 0 implants) 0.1 mm and (6-month tissues/implants)
1 mm. Day 0 specimens are both from dog 12. Unoperated cartilage images are from
the left femoral head of dog 13. Empty defect images are from the right femoral
head of dog 13, and the implant images are from dog 11.
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joint could articulate freely in seemingly a pain-free state as confirmed by actimetry, gait analysis, limb girth, and pain assessment.
Moreover, the mechanical properties also indicate values in the range
of normal articular cartilage, underscoring the functionality of the
tissues in the implant group at the 6-month time point. In total,
these histological and mechanical analyses strongly supported our
hypothesis that a tissue-engineered anatomically shaped implant
could restore structure and functional properties of the tissue and
then, as a consequence, that of the joint.
From a regulatory perspective, the implant used in this study would
require a Biological License Application as a combination product
regulated by both the Center for Biologics Evaluation and Research
and the Center for Devices and Radiologic Health. The work presented here serves as preliminary data, providing early efficacy data
on the approach with the bicomponent implant. Longer time points
and other preclinical work would be required before entering phase 1
clinical trials.
Despite being the standard of care in hip OA, total joint replacement is not an ideal procedure for the young human patient population presenting with hip degeneration because they would likely
require multiple revision surgeries in their lifetime, each iteration
posing additional complications, quicker implant failures, and overall decreased satisfaction. Hence, there is a critical need for new interventions that delay or halt the progression of OA and the need for
initial joint replacement. The approach for using such a construct as
presented in this manuscript would be to stave off a traditional total
hip arthroplasty procedure by providing pain relief and restoring an
active lifestyle in this young and active human patient population. An
important advantage of the method proposed is that the bioartificial
implant is expected to integrate with the native bone while preserving
the integrity of the bony structure of the joint. If, over time, disease
progresses to the point that total joint replacement is an appropriate
choice of treatment, then the joint could be readily converted to a
standard joint replacement procedure. Because little or no bone is
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Fig. 7. Modified O’Driscoll scoring per component and total score. Higher scores indicate better healing. Maximum score is 20 points. Groups not sharing the same
letter are statistically different (Student’s t test for comparisons of each pair, P < 0.05).
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Fig. 8. Instantaneous and equilibrium compressive moduli of implants at day of surgery and after 6 months in vivo. Groups not sharing the same letter are statistically different [analysis of variance (ANOVA), P < 0.05].

removed in the initial implantation of the implant, native bone is
preserved for resurfacing arthroplasty or total hip arthroplasty procedures. Consequently, there would be few potential drawbacks as
compared to an initial joint replacement surgery. Furthermore, because the components of the implant are bioresorbable, the risk of
adverse events due to small wear products is greatly reduced. Regarding resorption, the choice of PCL was also deliberate, given its long
resorptive profile in vivo on the order of years, the bioinert nature
of the material, and the lack of acidic by-products as it breaks down
(29, 30). Our expectation, given these characteristics, is that the newly
synthesized tissue will continue to remodel as more percentage of
the load is borne by the newly synthesized tissue as the PCL resorbs.
Longer preclinical studies and, perhaps, even clinical trials will be
required to fully assess the resorptive nature and functionality of this
tissue over time.
In summary, all functional outcome metrics including activity
measurement, dynamic and static gait/standing analysis, and radiographic monitoring demonstrated that the animals receiving the
implant returned to normal preoperative values by the 6-month time
period. These functional outcome measures are all highly relevant
to human patients. Furthermore, the osteochondral defect was placed
in a clinically relevant, load-bearing position, indicating that the
implant was able to effectively restore the functional capacity of the
joint at early times. Although the phenotype of the repair tissue is
not fully characterized, the data from histology, immunohistochemical, and mechanical analyses, in combination, confirm the
structural integrity of the implant, its integration with surrounding
tissues, and the restoration of the articular surface, thereby providing
a basis and explanation for the functional outcomes that we observed
in this study. On the basis of the clinically relevant outcome measures that were investigated, our data provide evidence that a textile-
based, anatomically shaped resorbable construct can be combined
with MSCs for a potential therapy for the treatment of early- to
moderate-stage OA.
MATERIALS AND METHODS

Animals
All animal procedures were approved by the North Carolina State
University Institutional Animal Care and Use Committee (#13-010-B).
Purpose-bred sexually intact male hound dogs (n = 16, 25 to 31 kg)
were purchased at 2 years of age from an approved vendor. Dogs
were assigned to a study group if deemed healthy and free of clinical
orthopedic disease based on clinical examination by a board-certified
orthopedic surgeon veterinarian, complete blood count, blood
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chemistry, and urinalysis. Bloodwork and urinalysis were also performed before termination. Dogs were sedated and radiographed to
evaluate for preexisting hip dysplasia, radiographic OA, and closure
of the proximal femoral growth plates. Following the initial evaluation,
12 dogs were randomly allocated to either control group (control;
n = 6) or tissue-engineered scaffold implant group (implant; n = 6).
The remaining dogs (n = 4) were adopted out because of preexisting
hip OA and/or behavior incompatibility with study requirements.
All allocated dogs underwent hip surgery on one side, and the
contralateral hip was used as the normal control. Surgery was performed on the coxofemoral joint with the least OA and associated
signs based on clinical assessment and radiography.
Dogs were housed in climate-controlled individual housing with
room temperature and humidity maintained at 23°C and 30 to 70%,
respectively. Rooms were on a 12:12 light:dark cycle (light time:
6:30 a.m. to 6:30 p.m.), with rotating enrichment toys and features.
The dogs were allowed to move freely inside their runs but were
acclimated for 2 months before surgery to lowered ceilings to prevent jumping up. The bedding area was placed on the floor with a
step-up of only 7.6 cm. The dogs were fed according to their caloric
needs and allowed ad libitum access to water during the study. The
dogs were walked on leash for 10 min a day until surgery for socialization, training to the leash, and enrichment. The dogs were
transported to the data collection room for 20 to 30 min/day for
acclimation to performance activities involving the study equipment
(e.g., trotting across the force plate and standing on the pressure-
sensitive walkway).
Perioperative management
Preemptive analgesia was provided by a fentanyl patch (75 or 100 g,
depending on dog weight) applied to the body wall. Dogs were premedicated with acepromazine (0.025 mg/kg, sc) and midazolam
(0.2 mg/kg, sc). An intravenous catheter was placed, and propofol
was administered to effect to induce general anesthesia. Anesthesia
was maintained using isoflurane carried in oxygen and delivered via
an endotracheal tube and circle circuit. Dogs ventilated spontaneously.
Vital signs were monitored with electrocardiography, pulse oximeter,
blood pressure (oscillometry), and capnography throughout
anesthesia and recovery. Epidural bupivacaine (0.5 mg/kg) and
preservative-free morphine (0.1 mg/kg) were administered preoperatively. Prophylactic antibiotics (cefazolin; 22 mg/kg, iv) were
given at least 15 min before surgery and then every 90 min during
surgery. Immediately after surgery, an adhesive bandage and Ioban
(3M, St. Paul, MN) were applied to the surgical wound and replaced
as needed until the wound was healed (approximately 5 to 7 days).
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Acetaminophen (15 mg/kg, q12h) and gabapentin (10 mg/kg, q12h,
given orally) were administered postoperatively for 21 days. Additional analgesia (0.1 to 0.2 mg/kg, sc, of meloxicam or 4.4 mg/kg of
carprofen orally) was provided if pain was detected on examination
(M.E. and B.D.X.L.) at any time.
Bone marrow aspiration
Dogs assigned to the implant group had bone marrow aspirated under
general anesthesia 6 to 8 weeks before surgery. Following aseptic
preparation of the area, bone marrow was collected from the proximal humerus using an 11G Jamshidi biopsy needle, and 10 to 15 ml
of bone marrow were collected into a syringe containing 2000 U of
heparin. Bupivacaine was injected locally following the procedure,
and carprofen was administered for a total of 3 days following the
procedure. Bone marrow was immediately transported on ice to the
laboratory for subsequent cell cultures.
Tissue-engineered implant
The implant (Fig. 1, A to D) consisted of a novel bicomponent
structure that combined a biomimetic 3D woven textile (Fig. 1A) for
reconstructing the cartilage layer with a porous 3D printed structure,
previously shown to have osteoconductive properties (31). Multifilament resorbable PCL yarns (EMS-GRILTECH, Domat, Switzerland)
measuring ~150 m in diameter were woven in three orthogonal
directions (x, y, and z directions) using 48 x-direction yarns/cm, 75
y-direction yarns/cm, and 12 z-direction yarns/cm, resulting in an
overall porosity of 52.5%. A schematic of the structure is depicted in
Fig. 1E. The 3D osteoconductive base (Fig. 1B) was manufactured
by direct extrusion (500 ± 50 m) using a 3D printer (EnvisionTEC
3D-Bioplotter). The textile and printed phases were bonded using
localized heat under microscopic guidance to integrate the structures. More specifically, by taking advantage of the ability of PCL to
retain heat, the top layer of the additively manufactured base was
heated to ~65°C, and then the textile is pressed into place to incorporate the layers under stereomicroscopic guidance. The resulting
interface can be seen in Fig. 1 (F and G). Both phases of the implant
were made using PCL of molecular weight 50 to 60 kDa. The bicomponent woven/printed PCL scaffolds were immersed in a 4 M
NaOH bath for 15 to 16 hours to clean the fibers and increase their
surface hydrophilicity.
Cell culture and seeding of scaffold
Collected bone marrow from the initial 10 to 15 ml of aspirate was
divided between two 50-ml centrifuge tubes, and phosphate-buffered
saline (PBS) was added to a total of 45 ml of volume per tube. Samples
were centrifuged for 15 min at 300g to create a pellet of cells. The
supernatant was aspirated, PBS was added, and the procedure was
repeated an additional three times until a loose, but clearly identifiable, pellet was obtained on the fourth PBS wash. The cell pellets
were resuspended in 30 ml of MSC expansion media—consisting of
Dulbecco’s modified Eagle’s medium (DMEM); 10% fetal bovine
serum; penicillin, streptomycin, and fungizone (P/S/F); and basic
fibroblast growth factor (1 ng/ml)—and were divided equally among
three T225 flasks. Expansion media (20 ml) was added to each flask
to give a final volume of 30 ml per flask. A complete medium exchange occurred after 24 hours and then three times per week until
cells were removed for implant seeding after 1 week. The cells were
removed using 0.05% trypsin EDTA (5 ml per flask) and incubated
at 37°C, 5% CO2 for 3 to 5 min. Cells were harvested into 10 ml of
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expansion media and pelleted at 200g for 5 min. The pellet was aspirated and resuspended at a concentration of 20 million cells/ml of
MSC expansion media. Cells were seeded in a 25-l volume to the
textile surface of the implant, and the scaffolds were placed in the
incubator (37°C, 5% CO2) and allowed to attach to the 3D woven
structure for 1 hour, after which the scaffolds were turned upside
down and 1 ml of media was added to each scaffold. After 2 days,
another 1 ml of expansion medium was added to the cultures and
cultured for another 14 days. The cell-seeded implants were subjected to complete media exchanges three times per week irrespective of medium. After 14 days in expansion medium, the cultures
were switched to chondrogenic medium consisting of DMEM-HG,
ascorbic acid (37.5 g/ml), 100 nM dexamethasone, 1× P/S,
1× insulin/transferrin/selenic acid (ITS+), and transforming growth
factor–3 (10 ng/ml) for an additional 28 days before implantation.
Surgery
A standard craniolateral approach to the selected coxofemoral joint
was performed. Following round ligament transection and joint
dislocation, a 1.1-mm diamond-tip K-wire was inserted into the
femoral head (midpoint between the round ligament and lateral edge
of the femoral head), perpendicular to the surface in all directions,
and to a depth of ~5 mm. A 10-mm-diameter custom-designed
cannulated end mill with a depth stop was placed over the K-wire,
and a 2-mm-deep osteochondral defect was created on the dorsal,
load-bearing aspect of the femoral head. The K-wire was only used
during the drilling of the defect to stabilize the cannulated end mill
and was then removed before placement of the implant. The osteochondral defect was then repaired with the cell-seeded scaffold
(Fig. 1, H to L) in the implant group (Fig. 1K) and left empty in the
control (empty defect) group (Fig. 1J). The fixation of the implant
relied on an optimized press interference fit with the prepared defect; no sutures, fibrin glue, or other fasteners were used to stabilize
the implant in the defect. The joint capsule was closed, and a prosthetic capsulorrhaphy was performed (32) using two 3.5-mm
dorsally placed screws and two strands of fiber wire (Arthrex Inc.,
Naples, FL) placed in a figure-of-eight pattern around each screw
and through a transosseous tunnel in the intertrochanteric area of
the femur (Fig. 1L). The capsulorrhaphy was performed so as not to
impair normal movement of the coxofemoral joint. The dogs were
allowed unrestrained weight bearing and normal activity in their
living areas for the first month. From the second month on, range
of motion (ROM) and leash-walking exercises were instigated. In
month 2 postoperatively, dogs received 5 min of leash walk and
30 cycles of ROM exercise on the operated hip joint twice daily.
During months 3 to 6, dogs received 10 min of leash walk twice
daily without any passive ROM exercises.
Outcome measures
Gait analysis
Kinetic gait analysis (33, 34) was performed on trotting dogs using
dual in-series force plates (Advanced Mechanical Technology Inc.,
Watertown, MA) preoperatively and every month following surgery.
Velocity and acceleration were measured by means of five photometric switches that were connected to the computer analysis system and were kept within 1.7 to 2.1 m/s and ± 0.5 m/s2, respectively.
Five trials were collected from each dog at each time point. A single
handler and computer operator performed all gait analysis throughout
the study period. Specialized computer software (Sharon software,
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Dewitt, MI) was used to calculate GRFs of the limbs. GRFs were
expressed in percent body weight. PVF, VI, PPF, and PI were
analyzed as previously demonstrated (33).
A pressure-sensitive walkway (7100 QL Virtual Sensor 4, Tekscan,
Boston, MA) was used to measure static GRF data (body weight
distribution) (17). Static data were acquired as previously described
(17, 35), preoperatively and every month postoperatively. For each
dataset, the mean percentage body weight distribution through
each limb over a steady 5-s period was recorded. Five replicates of
pressure-sensitive walkway data were acquired for each animal per
session (once per month) and used for analysis. GRFs (weight) were
expressed in percent body weight distributed to that limb.
Actimetry
One triaxial, omnidirectional accelerometer (Actical, Philips Respironics,
Bend, OR) was fixed onto the collar of each dog and worn throughout
the study to continuously record activity and therefore translational
movement (25). The recording epoch was set to 1 min, and data were
downloaded every 4 weeks. Data for the 2 weeks before each outcome
measure time point were extracted, and the activity over the 2-week
period was calculated on a per-hour basis by the following equation
i=1 i
_
∑
 14
j=1  ( 60 )  
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where Havg indicates average counts over a specific hour of the day
over a 2-week period, and Ci indicates measured counts for each
minute during the hour.
The times when dogs were removed from their cages for exercise
were manually recorded cage-side, and activity data from these time
periods were not included in the analysis. Thus, activity data only
reflected spontaneous activity in the cage.
Radiography, ROM, and limb girth measurement
Standard extended ventro-dorsal and lateral coxofemoral joint radiographic views and distraction index views (36) were obtained on each
animal preoperatively and every month for 6 months following surgery
under sedation with dexmedetomidine (5 g/kg, iv) and butorphanol
(0.3 mg/kg, iv). All images were anonymized and randomly assigned
an identification number using a free open source tool (DicomCleaner).
The ventro-dorsal images were scored for severity of OA by two experienced blinded observers (consensus scoring), using an 11-point
(0 to 10) numeric rating scale developed by the research team.
Cross-sectional area of the thigh via CT
Immediately before termination of the dogs, under sedation, CT
images (SOMATOM Perspective 64, Siemens Medical Solutions USA
Inc., Malvern, PA) were obtained of both hindlimbs from the cranial
border of iliac wing to just distal to the toes using a slice thickness of
1 mm and spacing of 10 mm. Scan parameters were set at 120 to
130 kilovolt peak and 21 to 129 mA by using a 25-cm field of view,
a 512 × 512 matrix. Cross-sectional area of the thigh was measured
at the midpoint of the distance between the most proximal point of
the greater trochanter and the midpoint of the lateral fabella using
ImageJ (setting the lower and upper thresholds to −29 and +150).
The difference in cross-sectional area (in square centimeters) between
hindlimbs (operated minus unoperated) was calculated in each dog.
Joint motion and muscle circumference
At each data collection time point, circumference (girth) of each thigh
was measured at point 70% of distance from the great trochanter to
fabella in the standing dog using Gulick II tape measure (Country
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Technology Inc., Gays Mills, WI). Measurements were obtained in
triplicate for each limb, and the mean value was used for analysis
(37). The difference in the limb girth between hindlimbs was calculated (operated − unoperated).
Pain assessment
The CROPI-h (fig. S1), developed for the assessment of OA-associated
pain and activity impairment in research dogs, was completed by a
single observer for each dog preoperatively and every month postoperatively. A summed score (out of a total of 150) was assigned to
each dog at each time point.
Histological assessment
Dogs were humanely terminated 6 months after surgery with an overdose of pentobarbital sodium and phenytoin sodium (Beuthanasia D
solution, Schering-Plough Animal Health Corp., Union, NJ). Femora
and acetabulae were harvested intact, wrapped in PBS-soaked gauze,
and frozen (−20°C) until analysis.
Joint histology and immunohistochemistry
Implant and control osteochondral defects were transected with a
low-speed diamond saw such that one-third of the osteochondral
defect could be processed by decalcified histology and the other
two-thirds of the defect could be processed by undecalcified histology
and microradiography. Following decalcification, sections of tissue
were stained with Alcian blue–periodic acid–Schiff, Safranin O/Fast
Green, hematoxylin and eosin (H&E), and Mallory Aniline Blue
connective tissue stain. For acetabula, only H&E decalcified histology
was performed. For undecalcified histology, plastic-embedded tissue
blocks were sectioned using low-speed diamond blades to an approximate thickness of 200 to 300 m. Differential staining using a
proprietary trichrome stain was performed to permit both histological and cytological differentiation. With this staining method, the
following tissues can be differentiated on the basis of color: Bone is
stained green, cartilage and fibrocartilage are stained dark purple,
and fibrovascular tissue is stained pink.
For immunohistochemical analysis, antigen retrieval for sections
labeled for type II collagen was performed using Digest-All (Life
Technologies). Antigen retrieval for type I collagen slides was accomplished by submerging sections in pH 6.0 citrate buffer, and the
buffer was brought to a boil in a microwave and then maintained at
a sub-boiling temperature for 10 min. Monoclonal antibodies were
used to identify type I collagen (diluted 1:400; rabbit anti–collagen I
from Cell Signaling Technology, catalog no. 72026) and type II collagen (diluted 1:1; II-II6B3 from Developmental Studies Hybridoma
Bank, University of Iowa, Iowa City, IA). The secondary antibody
for type I collagen was the SignalStain Boost IHC Detection Reagent
[horseradish peroxidase (HRP), rabbit] (Cell Signaling Technology,
catalog no. 8114). For type II collagen, the secondary antibody was
the SignalStain Boost IHC Detection Reagent (HRP, mouse) (Cell
Signaling Technology, catalog no. 8125). Briefly, sections were
covered with secondary solution (approximately 150 l per section)
and incubated with the secondary antibody solutions for 1 hour
at room temperature. A DAB (3,3′-diaminobenzidine) chromogen
was used for antigen labeling (DAB Substrate Kit, BD Pharmingen,
catalog no. 550880).
A qualitative assessment of bone healing and cartilage repair was
made within the osteochondral defects. In addition, a modified scoring
system based on the O’Driscoll scale (38) (20 points in total) was
used to evaluate all control femora and osteochondral defects. The
O’Driscoll scale measured surface irregularity (3 points), cartilage level
within the defect (2 points), bonding to adjacent cartilage (2 points),
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regenerated subchondral bone (2 points), inflammatory cell inflammation around the implant (2 points), chondrocyte clustering
(2 points), freedom from degenerative changes (3 points), and
hyalinity (4 points).
Biochemical analysis
A section of day 0 constructs was removed and digested in papain for
12 hours at 58°C. DNA was measured using the Quant-iT PicoGreen
dsDNA assay (Life Technologies). sGAG was measured using the
dimethylmethylene blue assay using chondroitin 4-sulfate as a standard and reading the optical density on a plate reader (595 nm). For
total collagen content, OHP was measured by hydrolyzing the digest
in HCl and reacting the solution with p-dimethylaminobenzaldehyde
and chloramine-T to measure OHP content per construct. Total
collagen was then determined using 0.134 as the ratio of OHP to
collagen (18).
Mechanical testing
Indentation testing was used to measure the compressive modulus
of the articular cartilage of both the operated and contralateral control (unoperated) joints, as well as the day 0 implants. A minimum
of three points were evaluated at the following locations: on the repair tissue, outside of the repair tissue on the treated limb, the contralateral control cartilage in the dorsal, load-bearing region, and on
the articular surface of the day 0 implants. Indentation testing was
performed using an ElectroForce testing instrument (TA Instruments,
New Castle, DE), ensuring normality to the surface, and using a
spherical 4-mm indenter to perform three compressive stress-
relaxation steps at 5, 10, and 15% strain steps with a 10-min dwell
following each step to allow the cartilage and de novo synthesized
tissues to reach equilibrium. The resulting force-displacement data
at 10%  were then fit to a viscoelastic indentation model described
by a modified Hertz equation (39, 40) to determine the instantaneous
and equilibrium modulus of the tissues.
Pathology assessment
Synovium samples were taken from dorsal, ventral, medial, and lateral
sections of the operated and contralateral control joints to assess for
inflammation. Briefly, the tissues were fixed in 10% neutral buffered
formalin followed by processing for routine paraffin-embedded
decalcified histology (11). All sections were stained with H&E and
graded by a trained pathologist (D.J.V.) for chronic inflammation,
synovial hyperplasia, and the presence of giant cells with a semiquantitative four-point scoring system: normal, 0; mild, 1; moderate,
2; and severe, 3.
Statistical analysis
A longitudinal statistical analysis was performed to compare the
two treatment groups across the postoperative time points. For the
operated joint, dijk denotes the difference between the response at
the kth time point (k = 1,…,6) and its preoperative measurement for
the jth subject (j = 1,…,6) in the ith treatment group (i = 1, 2). The
preoperative measurement is denoted xij. For all responses except
the actimetry data, a two-way analysis of covariance (ANCOVA)
model was used with responses dijk, covariate xij, and two factors:
treatment and time. The treatment/time interaction effect was included in the model but removed when found to be statistically insignificant. The covariate effect was included because the range of
values for dijk and the time required to return to baseline can depend
on xij. A heterogenous, lag-1 autoregressive [abbreviated as AR(1)]
covariance structure was assumed that allowed different variances
for the six time points. For mechanical testing, the raw scores had
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large outliers, so two analysis approaches were taken: a two-sample
t test using a log transformation and unequal variances and a nonparametric Wilcoxon test.
Analysis of the actimetry data was performed on dijkl, the lth hourly
difference between the measurements at time point k and the preoperative measurements, xijl. A three-way ANCOVA mixed model
was fitted, having all main and two-way interactions between the
factors treatment, time point, and hour as fixed effects and random
effects for each subject as well as the subject/time point interaction
effects. The subject/time point interaction random effects were
assigned a homogenous, AR(1) covariance structure, while the
residual effects were assumed to have a heterogeneous, AR(1)
covariance structure.
For each response, we first fit the interaction model described
above. If the interaction effect was significant, then we reported which
time points exhibited significant differences between the treatment
groups and their effect sizes. If the time point/treatment interaction
effects were insignificant, then the effects were dropped from the
model, but all other effects were left in the model regardless of their
statistical significance. Analyses were performed using PROC MIXED
in SAS 9.4. Statistical tests were performed using the Kenward-Roger
denominator degrees of freedom method. Statistical significance
was based on a significance level of 0.05. Post hoc comparisons that
were performed using Tukey adjustments were used to correct for
multiple testing.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abi5918
View/request a protocol for this paper from Bio-protocol.
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